India’s COVID-19 tally breaches 23-lakh mark; Phase two human trials of COVAXIN begins.
India reports fresh 60,963 Coronavirus infections, with 834 deaths; COVAXIN’s phase two of human trials at Nagpur hospital.
India reports fresh 60,963 COVID-19 virus infections in the last 24 hours, which breached the country’s Coronavirus tally over 23-lakh mark. The fresh surge in cases has taken the tally to 23,29,638. The number of deaths in the country rose 46,091 after registering a total of new 834 causalities. The recovery rate of India has improved to 70.37 percent after recovered patients’ tally rose to 16,39,599. India’s mortality rate fell to 1.99 percent and daily testing numbers increased to 733,449.
Biggest single-day tally of coronavirus infections in Maharashtra:
Maharashtra registered its biggest single-day tally with more than 12,712 coronavirus infections on Wednesday, taking the tally to 548,313 in the state. New 344 deaths were registered in the state, which took the death toll in the worst-affected COVID-19 state to 548,313. Mumbai reported new 1132 cases and 50 deaths in the last 24 hours.
COVAXIN’s phase 2 human trials begin at Nagpur hospital:
After Russia registered the world’s first COVID-19 vaccine yesterday, India started phase 2 human trials of its prime vaccine candidate on Wednesday at a Nagpur hospital. COVAXIN, India’s vaccine, has been jointly developed by the Hyderabad-based Bharat Biotech with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). After a successful initial phase 1 trial, carried out in AIIMS, the Drug Controller General of India has green-lit phase two of human trails. Hundreds of people will be tested, to gather more information about the side-effects and immune system response to the vaccine.
Globally, more than 20.3 million people have been infected with the fatal virus and over 741,000 people have died.
